September 12, 2025 – The winners of the Lasker Awards, known as the “America’s Nobels", was officially announced on September 11. Dr. Steven McKnight, Scientific Advisor and Shareholder of TenNor Therapeutics, was awarded the Lasker Basic Medical Research Award for discoveries into the role of proteins of low sequence complexity and their influence on the dynamics of cell morphology and biological regulation.

September 11, 2025 – The results of the Phase III clinical trial for rifasutenizol (TNP-2198), a global first-in-class drug developed by TenNor Therapeutics for the treatment of Helicobacter pylori infection, have been published online in the prestigious international journal The Lancet Infectious Diseases.

August 22, 2025 – TenNor Therapeutics (Suzhou) Limited announced that the New Drug Application (NDA) for its first-in-class drug product, Rifasutenizol (TNP-2198) capsules, for the treatment of Helicobacter pylori (H. pylori) infection, has been accepted by the National Medical Products Administration (NMPA) of China.

May 5, 2025 – TenNor’s new drug for H. pylori infection, Rifasutenizol (TNP-2198) made its debut at Digestive Disease Week (DDW) 2025 in San Diego, USA. A conference abstract titled “The Efficacy and Safety of Rifasutenizole (TNP-2198) Based Triple Regimen as First-Line Therapy For Helicobacter pylori Infection: A Multicenter, Double-Blind, Randomized, Controlled, Phase 3 Trial”, submitted by Professor Zhou Liya and Professor Song Zhiqiang from Peking University Third Hospital, along with Professor Wang Weihong from Peking University First Hospital, was selected for presentation at the Distinguished Abstract Plenary Session.

March 21, 2025 – TenNor Therapeutics announced the official initiation of a Phase II clinical trial for its first-in-class drug, TNP-2092, administered via intra-articular injection for the treatment of prosthetic joint infections (PJI). This significant milestone marks a crucial step forward for TenNor in addressing major unmet medical needs in the field of infectious diseases, offering new hope to millions of patients worldwide suffering from infections related to implanted medical devices.

February 26, 2025, Basel, Switzerland – TenNor Therapeutics presented its novel multi-targeting drug conjugation technology as a solution to antimicrobial resistance (AMR) problems at the 9th AMR Conference.

SUZHOU, China, Nov. 28, 2024 -- TenNor Therapeutics announced that it has entered an exclusive commercial partnership agreement with Grand Life Sciences (“GLS”) Group for rifasutenizol (TNP-2198) for the treatment of H. pylori infection. Under the agreement, TenNor licenses GLS’s wholly-owned subsidiary, Hangzhou Grand Biologic Pharmaceutical INC. ("Hangzhou Grand"), to exclusively commercialize and promote rifasutenizol in mainland China, Hong Kong and Macau.

SUZHOU, China, Nov. 18, 2024 -- TenNor Therapeutics, a clinical-stage company dedicated to developing novel therapies to address unmet needs in infectious diseases, announced today the successful completion of a phase III clinical trial of rifasutenizol (TNP-2198) for the treatment of Helicobacter pylori (H. pylori) infection. The study met its primary endpoints, showing multiple advantages of rifasutenizol regimen compared with bismuth-containing quadruple therapy (BQT), the current standard of care.